Inovio Pharmaceuticals (INO)' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies

Inovio Pharmaceuticals (INO)' DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study

BLUE BELL, Pa., June 30, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved compelling immune responses in a study of its multi-subtype DNA vaccine for foot-and-mouth (FMD) disease administered by Inovio's proprietary vaccine delivery technology in sheep, the second large animal in which this vaccine was evaluated. Strong protective neutralizing antibodies were also observed in pigs vaccinated with the same Inovio FMD vaccine. These results were presented by Dr. Niranjan Y. Sardesai, Inovio Sr. VP of Research and Development, at the Biochemical and Molecular Engineering XVII Conference in Seattle in a talk titled "Engineering Effective Consensus DNA Vaccines." Today's FMD vaccines based on killed/inactivated viruses can actually cause FMD infection, so are only used regionally after an outbreak rather than for broad preemptive vaccination. Inovio's synthetic DNA vaccine cannot cause the disease, providing a safe approach to potentially protect against FMD and reduce its serious impact on global food supply and commerce.

The FMD virus is one of the most infectious agents causing significant disease in farm animals including cattle, swine, sheep and goats. Once an area is exposed to FMD, livestock & dairy exports are ceased and herds are culled. For example, in a major FMD outbreak in the UK in 2001, more than 4 million animals were slaughtered, resulting in more than $10 billion (USD) in economic losses. In a current FMD epidemic in South Korea, more than 3.3 million animals, mostly swine, have been culled in an attempt to keep the disease from spreading.

Because FMD can spread rapidly and beyond regional boundaries there is a need to develop vaccines that can simultaneously target different regional serotypes (subtypes) of FMD in a single vaccine. Inovio's SynCon technology enables rapid development of vaccines that can cover multiple subtypes simultaneously with a single formulation. Inovio and its academic collaborators have generated and successfully tested SynCon DNA vaccine constructs targeting four of the seven main FMD virus subtypes.

FMD is highly infectious. Furthermore, due to the fear of inadvertent spread to farm animals, research with the live virus to test vaccine efficacy is heavily restricted to only a few government laboratories in the US. The investigators therefore developed a new proprietary neutralization assay (using a mock virus unrelated to FMD to assess the ability of the vaccine-induced antibodies to neutralize virus infection). Inovio previously reported the induction of strong cellular and antibody responses in vaccinated pigs after a single vaccination. In a follow-on investigation of the immune responses with the novel neutralization assay against the Asia strain, the vaccinated animals developed neutralizing antibody (NAb) titers averaging 90 after a single vaccination and increasing in magnitude to 191 after two vaccinations. For comparison, commercially available attenuated/killed FMD virus vaccines are able to protect swine with an NAb titer of 32-40. These results are the first report of a DNA vaccine producing high titers of neutralizing antibodies against FMD.

In the second large-animal study, sheep were vaccinated three times at 0, 5, and 10 weeks with a combination vaccine targeting either four subtypes (O, A, C, Asia), three subtypes (O, A, Asia), or a single subtype (Asia). The study investigators observed in the vaccinated animals high levels of seroconversion (production of antibodies specific to a particular antigen) and antibody titers (the actual level of antibody production; in this case, ranging from 1000 100,000) to all the vaccine subtypes after only one or two vaccinations. Importantly, the multi-subtype DNA vaccines targeting three or four subtypes simultaneously were able to induce equally strong levels of antibody titers compared to the single-subtype vaccines. Strong T-cell responses (cumulatively > 1,500 SFU/million PBMC), which would potentially play a role in treating the disease, were also noted against the four different subtype antigens. Speaking at the meeting, Dr. Sardesai noted, "Encouraged by these results with four subtypes, we are now expanding the coverage of our vaccine to include the three additional key circulating subtypes SAT 1, 2, 3 and will initiate further large animal studies to assess breadth of protection."

Dr. J. Joseph Kim, Inovio's president and CEO, said: "We are pleased to demonstrate these robust DNA vaccine immune responses in a second globally-important farm animal impacted by foot-and-mouth disease. FMD pandemics are a worldwide threat to food supply and society, and the limitations of today's FMD vaccines means they are not able to facilitate adequate protection. Inovio's FMD vaccine program could provide a global solution to this menacing threat to our world's food supply. We look forward to further developing this important vaccine."

About Foot-and-Mouth Disease

Foot-and-mouth disease (FMD) affects cloven-hoofed animals such as cattle, pigs, sheep, goats and water buffalo, and is capable of rapidly infecting large numbers of animals. Seven main types of FMD virus are believed to exist today. Like other viruses, the FMD virus continually evolves and mutates. To date there has been no cross-protection between strains even within the different subtypes of the FMD virus. Vaccine viruses which are not completely killed have resulted in FMD outbreaks, hence vaccines used today are administered to the herd only once an outbreak is detected in an area in order to limit the rapid spread of infection, thus limiting the potential utility of such vaccines.

While death rates are generally low, the highly infectious nature of the virus has a profound negative economic impact, such as in the dairy industry where cattle may experience reduced milk production, poor growth and permanent hoof damage. An FMD outbreak typically leads to economic sanctions, including the loss of export markets, and can negatively impact tourism as restrictions are placed on the movement of people and animals. This was the case in the 2001 outbreak in the UK.

About Inovio Pharmaceuticals, Inc.

Inovio is developing a new generation of vaccines, called DNA vaccines, to treat and prevent cancers and infectious diseases. Its SynCon vaccines are designed to provide broad cross-strain protection against known as well as newly emergent strains of pathogens such as influenza. These vaccines, in combination with Inovio's proprietary electroporation delivery devices, have been shown to be safe and generate significant immune responses. Inovio clinical programs include three Phase II studies for vaccines treating cervical dysplasia/cancer, hepatitis C virus, and leukemia. Other clinical programs target influenza (preventive) and HIV (preventive and therapeutic). Inovio partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spin-out company SpringWorks has lost president and founder Lara Sullivan, M.D. who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.